Key result
Transapical SAPIEN 3 without preballooning is linked to similar 30-day mortality but less contrast and radiation.
Why the study?
Preballooning is commonly used during transapical TAVI, but the safety and outcomes of SAPIEN 3 valve implantation without preballooning have not been evaluated.
Does transcatheter aortic valve implantation without preballooning improve procedural outcomes and safety compared to standard preballooning in patients undergoing transapical SAPIEN 3 valve implantation?
Cohort (n=66)
No
Does transcatheter aortic valve implantation without preballooning improve procedural outcomes and safety compared to standard preballooning in patients undergoing transapical SAPIEN 3 valve implantation?
Direct transapical SAPIEN 3 valve implantation without preballooning is feasible, safe, and associated with reduced contrast use, radiation dose, and new pacemaker implantations compared to standard preballooning.
Answers are grounded in this paper and cite their sources.
May reduce contrast and radiation in transapical TAVI; hypothesis-generating and requires randomized confirmation before practice change.
OBJECTIVE: Preballooning (PB) of the stenotic aortic valve can be considered common standard during transcatheter aortic valve implantation (T-AVI). Transcatheter aortic valve implantation without preballooning (noPB) using the Edwards SAPIEN XT prosthesis has been described previously. The aim of this study was to evaluate the outcomes of next-generation SAPIEN 3 valve implantation without PB. METHODS: Since January 2013, a total of 66 patients received SAPIEN 3 valve implantation at our center using the transapical approach. Patients were treated using the standard PB technique (n = 17 [25.8%]) or no PB (n = 49 [74.2%]). RESULTS: Baseline characteristics of patient groups were comparable (38% women; mean age, 83 years; STS score, 8%, logistic EuroSCORE I and II, 30% and 8%, respectively). Patients in the PB group were exclusively treated in our earlier experience with this device. Overall 30-day mortality was 4.5% (6.1% for noPB vs. 0% PB; P = ns). Aortic regurgitation was grade 1 or less in 100% (PB) versus 93.9% (noPB); P = ns Median contrast use was 70 (60-95) mL (PB) versus 50 (40-50) mL (noPB); P < 0.001; and median radiation dose was 32.0 (17-57) Gy × cm (PB) versus 26.6 (16-36) Gy × cm (noPB); P < 0.001. Postdilatation was required in one patient only (noPB). The rate of new pacemaker implantations was 41.2% (PB) versus 12.2% (noPB); P = 0.03. Periprocedural stroke occurred in one patient in each group (6% PB vs 2.0% no-PB); P = ns. CONCLUSIONS: Direct transapical SAPIEN 3 valve implantation without PB is feasible and safe. The no-PB technique leads to further simplification of the procedures.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2015) conducted a cohort in Stenotic aortic valve (n=66). Transcatheter aortic valve implantation without preballooning vs. Standard preballooning technique was evaluated on 30-day mortality (p=ns). Transapical SAPIEN 3 valve implantation without preballooning had similar 30-day mortality to preballooning but reduced contrast use and radiation dose.
Synapse has enriched 10 related papers. Consider them for comparative context: